Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 16/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912324 | 0.82 | MTOR (0.52) | MTORMAPTPIK3R1PIK3CAESR2 | |
| SCHEMBL412843 | 0.77 | MTOR (0.61) | MTORPIK3R1PIK3CA | |
| SCHEMBL443862 | 0.77 | MTOR (0.61) | MTORPIK3R1PIK3CA | |
| SCHEMBL30685427 | 0.76 | ESR2 (0.53) | MAPTESR2 | |
| SCHEMBL18550196 | 0.76 | ESR2 (0.53) | MAPTESR2 | |
| SCHEMBL24955630 | 0.76 | MTOR (0.55) | MTORPIK3R1PIK3CA | |
| SCHEMBL31107005 | 0.76 | MTOR (0.55) | MTORPIK3R1PIK3CA | |
| SCHEMBL442685 | 0.76 | MTOR (0.55) | MTORPIK3R1PIK3CA | |
| SCHEMBL412512 | 0.76 | MTOR (0.55) | MTORPIK3R1PIK3CA | |
| SCHEMBL15196064 | 0.75 | MTOR (0.74) | MTORPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2216023-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | HTR2C, HTR5A, HTR3C | MTOR 1470/4885MAPT 4660/4885PIK3R1 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.